Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Merrimack Files S-1, But Life-Science IPO Market Far From Ironclad

This article was originally published in The Pink Sheet Daily

Executive Summary

The cancer drug maker aims to raise as much as $172.5 million and bring liquidity to investors who have poured in more than $250 million.

You may also be interested in...

Aveo Signs J&J As Partner In Early-Stage RON Antibody Deal

Given the early-stage nature of the collaboration, Aveo will receive $15 million upfront for preclinical antibodies targeting the RON receptor.

Astellas Pays $125MM Up-Front To Share Rights To AVEO's Tivozanib

In a worldwide deal excluding Asia, the two companies will split both revenues and development costs 50/50 in North America and Europe.

Sanofi Broadens Portfolio By Licensing A Monoclonal Antibody From Merrimack

Privately held Merrimack gets $60 million upfront for MM-121, a monoclonal antibody in Phase I/II.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts